Noncanonical T cell responses are associated with protection from tuberculosis in mice and humans
Journal of Experimental Medicine · 2025
DOI: 10.1084/jem.20241760 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2025. Verfasst von Megan K Proulx und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, University of Massachusetts Chan Medical School, Worcester, MA, USA. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NIDA NIH HHS.
Abstract (Originalsprache)
While control of Mycobacterium tuberculosis (Mtb) infection is generally understood to require Th1 cells and IFNγ, infection produces a spectrum of immunological and pathological phenotypes in diverse human populations. By characterizing Mtb infection in mouse strains that model the genetic heterogeneity of an outbred population, we identified strains that control Mtb comparably to a standard IFNγ-dependent mouse model but with substantially lower lung IFNγ levels. We report that these mice have a significantly altered CD4 T cell profile that specifically lacks the terminal effector Th1 subset and that this phenotype is detectable before infection. These mice still require T cells to control bacterial burden but are less dependent on IFNγ signaling. Instead, noncanonical immune features such as Th17-like CD4 and γδT cells correlate with low bacterial burden. We find the same Th17 transcriptional programs are associated with resistance to Mtb infection in humans, implicating specific non-Th1 T cell responses as a common feature of Mtb control across species.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
- Transgenic Animal Modeling Core, University of Massachusetts Chan Medical School , Worcester, MA, USA.
- University of Pittsburgh School of Medicine , Pittsburgh, PA, USA.
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard , Cambridge, MA, USA.
- Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA.
ORCID-Profile: Megan K Proulx, Christine D Wiggins, Charlotte J Reames, Claire Wu, Michael C Kiritsy, Ping Xu, Judith C Gallant, Patricia S Grace, Brooke A Fenderson, Clare M Smith, Cecilia S Lindestam Arlehamn, Galit Alter, Douglas A Lauffenburger, Christopher M Sassetti
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
- NIDA NIH HHS
- NIH HHS
- HHS
- ORFDO NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
Zitieren
APA
Proulx, M. K., Wiggins, C. D., Reames, C. J., Wu, C., Kiritsy, M. C., Xu, P., Gallant, J. C., Grace, P. S., Fenderson, B. A., Smith, C. M., Lindestam Arlehamn, C. S., Alter, G., Lauffenburger, D. A., & Sassetti, C. M. (2025). Noncanonical T cell responses are associated with protection from tuberculosis in mice and humans. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20241760
Vancouver
Proulx MK, Wiggins CD, Reames CJ, Wu C, Kiritsy MC, Xu P, et al. Noncanonical T cell responses are associated with protection from tuberculosis in mice and humans. Journal of Experimental Medicine. 2025. doi:10.1084/jem.20241760
BibTeX
@article{Proulx2025,
author = {Proulx, Megan K and Wiggins, Christine D and Reames, Charlotte J and Wu, Claire and Kiritsy, Michael C and Xu, Ping and Gallant, Judith C and Grace, Patricia S and Fenderson, Brooke A and Smith, Clare M and Lindestam Arlehamn, Cecilia S and Alter, Galit and Lauffenburger, Douglas A and Sassetti, Christopher M},
title = {Noncanonical T cell responses are associated with protection from tuberculosis in mice and humans},
journal = {Journal of Experimental Medicine},
year = {2025},
doi = {10.1084/jem.20241760}
}
EUVIMED